PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncogene

• Publication date

  2017-01-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2016.469PMID 28092671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PARKIN Inactivation Links Parkinson's Disease to Melanoma.

  2016cited by this paper
• Genomic Classification of Cutaneous Melanoma.

  2015cited by this paper
• Cyclic AMP (cAMP) signaling in melanocytes and melanoma.

  2014cited by this paper
• Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology.

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• FAK in cancer: mechanistic findings and clinical applications

  2014cited by this paper
• Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.

  2014cited by this paper
• Phosphodiesterase 4D Inhibitors Limit Prostate Cancer Growth Potential

  2014cited by this paper
• Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF

  2013cited by this paper
• MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells

  2013cited by this paper
• A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

  2013cited by this paper
• Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers

  2013cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Mutant BRAF melanomas--dependence and resistance.

  2011cited by this paper
• ERK and PDE4 cooperate to induce RAF isoform switching in melanoma

  2011cited by this paper
• A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity.

  2010cited by this paper
• Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit.

  2010cited by this paper
• Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.

  2010cited by this paper
• Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.

  2009cited by this paper
• Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression

  2008cited by this paper
• Identification of cells initiating human melanomas

  2008cited by this paper
• A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.

  2007cited by this paper
• Melanocyte biology and skin pigmentation

  2007cited by this paper
• Targeting Mutant V600EB‐Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation

  2007cited by this paper
• MC1R Germline Variants Confer Risk for BRAF-Mutant Melanoma

  2006cited by this paper
• MC1R germline variants confer risk for BRAF-mutant melanoma.

  2006cited by this paper
• Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

  2006cited by this paper
• In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

  2006cited by this paper
• Focal adhesion kinase promotes the aggressive melanoma phenotype.

  2005cited by this paper
• Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility

  2004cited by this paper
• PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

  2003cited by this paper
• Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling*

  2003cited by this paper
• Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.

  2003cited by this paper
• Targeting of Cyclic AMP Degradation to β2-Adrenergic Receptors by β-Arrestins

  2002cited by this paper
• Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins.

  2002cited by this paper
• Cyclic AMP Blocks Cell Growth through Raf-1-Dependent and Raf-1-Independent Mechanisms

  2002cited by this paper
• Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair.

  2001cited by this paper
• The RACK1 Signaling Scaffold Protein Selectively Interacts with the cAMP-specific Phosphodiesterase PDE4D5 Isoform*

  1999cited by this paper

• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• BTSCs exosomes derived NamiRNA-enhancer network of miR-151a-3p mediates a positive feedback loop and promotes the progression of glioma via FAK phosphorylation.

  2025cites this paper
• Cross-species analysis identifies genotype-driven vulnerabilities in lung adenocarcinoma

  2025cites this paper
• Single-nucleus multiomics in brains from Hispanic individuals reveal APOE-ε4-driven disruption of focal adhesion signaling in the presence of cerebrovascular pathology

  2025cites this paper
• Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: Synthesis, mechanistic Insights and promising antitumor and safety profile

  2024cites this paper
• Regulation of intracellular cAMP levels in osteocytes by mechano-sensitive focal adhesion kinase via PDE8A

  2024cites this paper
• PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors

  2024influential citation
• Nanodomain cAMP signalling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

  2024cites this paper
• Single-cell hdWGCNA reveals metastatic protective macrophages and development of deep learning model in uveal melanoma

  2024cites this paper
• Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models

  2023cites this paper
• Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance

  2023cites this paper
• Is Apremilast a Safe Option in Patients with History of Melanoma? A Case Series and a Review of the Literature.

  2022cites this paper
• Integrative QTL mapping and selection signatures in Groningen White Headed cattle inferred from whole-genome sequences

  2022cites this paper
• Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma

  2022cites this paper
• miR-5701 promoted apoptosis of clear cell renal cell carcinoma cells by targeting phosphodiesterase-1B

  2021cites this paper
• Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells

  2021cites this paper
• Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma

  2021cites this paper
• The Mouseion at the JAXlibrary The Mouseion at the JAXlibrary

  2021cites this paper
• Cyclic adenosine monophosphate (cAMP) signaling in melanocyte pigmentation and melanomagenesis

  2020cites this paper
• Whole-genome screen identifies diverse pathways that negatively regulate ciliogenesis

  2020cites this paper
• CRTC3 is a coincidence detector for cAMP and growth factor signals in melanocytes and melanoma.

  2020cites this paper
• PDE4 subtypes in cancer

  2020cites this paper
• Transcriptional co-activator regulates melanocyte differentiation and oncogenesis by integrating cAMP and MAPK/ERK pathways

  2020cites this paper
• Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway.

  2019cites this paper
• Yin and Yang of Pluripotency: Results of Analysis of Genes Overexpressed In Tumor-Initiating Cells of Krebs-2 Ascites Carcinoma

  2019cites this paper
• Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.

  2019cites this paper
• High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma

  2019cites this paper
• Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

  2019cites this paper
• Design and synthesis of 1,2,4‐triazolo[1,5‐a]pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activity

  2019cites this paper
• Cutaneous hyperpigmentation induced by apremilast

  2018cites this paper
• Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.

  2018cites this paper
• Piwi like RNA-mediated gene silencing 1 gene as a possible major player in gastric cancer

  2018cites this paper
• Cancer Stem Cells: Emergent Nature of Tumor Emergency

  2018cites this paper
• Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions

  2018cites this paper